Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
The prognosis of high-risk neuroblastoma is poor despite the availability of multimodal treatment. Here the authors show that high-risk neuroblastoma is sensitive to indisulam, a selective degrader of the splicing factor RBM39 through the dual targeting of RNA splicing and metabolism.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-28907-3 |
| _version_ | 1818774740143177728 |
|---|---|
| author | Anke Nijhuis Arti Sikka Orli Yogev Lili Herendi Cristina Balcells Yurui Ma Evon Poon Clare Eckold Gabriel N. Valbuena Yuewei Xu Yusong Liu Barbara Martins da Costa Michael Gruet Chiharu Wickremesinghe Adrian Benito Holger Kramer Alex Montoya David Carling Elizabeth J. Want Yann Jamin Louis Chesler Hector C. Keun |
| author_facet | Anke Nijhuis Arti Sikka Orli Yogev Lili Herendi Cristina Balcells Yurui Ma Evon Poon Clare Eckold Gabriel N. Valbuena Yuewei Xu Yusong Liu Barbara Martins da Costa Michael Gruet Chiharu Wickremesinghe Adrian Benito Holger Kramer Alex Montoya David Carling Elizabeth J. Want Yann Jamin Louis Chesler Hector C. Keun |
| author_sort | Anke Nijhuis |
| collection | DOAJ |
| description | The prognosis of high-risk neuroblastoma is poor despite the availability of multimodal treatment. Here the authors show that high-risk neuroblastoma is sensitive to indisulam, a selective degrader of the splicing factor RBM39 through the dual targeting of RNA splicing and metabolism. |
| first_indexed | 2024-12-18T10:45:56Z |
| format | Article |
| id | doaj.art-c91ed6203d624310b8e94805ee7888bd |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-18T10:45:56Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-c91ed6203d624310b8e94805ee7888bd2022-12-21T21:10:33ZengNature PortfolioNature Communications2041-17232022-03-0113111610.1038/s41467-022-28907-3Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastomaAnke Nijhuis0Arti Sikka1Orli Yogev2Lili Herendi3Cristina Balcells4Yurui Ma5Evon Poon6Clare Eckold7Gabriel N. Valbuena8Yuewei Xu9Yusong Liu10Barbara Martins da Costa11Michael Gruet12Chiharu Wickremesinghe13Adrian Benito14Holger Kramer15Alex Montoya16David Carling17Elizabeth J. Want18Yann Jamin19Louis Chesler20Hector C. Keun21Department of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDivision of Clinical Studies, The Institute of Cancer ResearchDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDivision of Clinical Studies, The Institute of Cancer ResearchDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDivision of Clinical Studies, The Institute of Cancer ResearchDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonDepartment of Surgery & Cancer, Imperial College LondonMedical Research Council London Institute of Medical ScienceMedical Research Council London Institute of Medical ScienceMedical Research Council London Institute of Medical ScienceDepartment of Metabolism, Digestion and Reproduction, Imperial College LondonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London and Royal Marsden NHS TrustDivision of Clinical Studies, The Institute of Cancer ResearchDepartment of Surgery & Cancer, Imperial College LondonThe prognosis of high-risk neuroblastoma is poor despite the availability of multimodal treatment. Here the authors show that high-risk neuroblastoma is sensitive to indisulam, a selective degrader of the splicing factor RBM39 through the dual targeting of RNA splicing and metabolism.https://doi.org/10.1038/s41467-022-28907-3 |
| spellingShingle | Anke Nijhuis Arti Sikka Orli Yogev Lili Herendi Cristina Balcells Yurui Ma Evon Poon Clare Eckold Gabriel N. Valbuena Yuewei Xu Yusong Liu Barbara Martins da Costa Michael Gruet Chiharu Wickremesinghe Adrian Benito Holger Kramer Alex Montoya David Carling Elizabeth J. Want Yann Jamin Louis Chesler Hector C. Keun Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma Nature Communications |
| title | Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma |
| title_full | Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma |
| title_fullStr | Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma |
| title_full_unstemmed | Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma |
| title_short | Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma |
| title_sort | indisulam targets rna splicing and metabolism to serve as a therapeutic strategy for high risk neuroblastoma |
| url | https://doi.org/10.1038/s41467-022-28907-3 |
| work_keys_str_mv | AT ankenijhuis indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT artisikka indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT orliyogev indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT liliherendi indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT cristinabalcells indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT yuruima indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT evonpoon indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT clareeckold indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT gabrielnvalbuena indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT yueweixu indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT yusongliu indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT barbaramartinsdacosta indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT michaelgruet indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT chiharuwickremesinghe indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT adrianbenito indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT holgerkramer indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT alexmontoya indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT davidcarling indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT elizabethjwant indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT yannjamin indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT louischesler indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma AT hectorckeun indisulamtargetsrnasplicingandmetabolismtoserveasatherapeuticstrategyforhighriskneuroblastoma |